<unk>  associated with a mutation in PDGFRA is treatable with imatinib and has an excellent prognosis. On the other hand,<unk>  associated with FGFR1 mutations has a very poor prognosis. Progression can occur from<unk>  to AEL or AML in rare cases.
Chronic eosinophilic leukemia
Acute eosinophilic leukemia
Tropical eosinophilia
Thymoma with immunodeficiency
Diffuse infiltrative lymphocytosis syndrome
Hemophagocytic lymphohistiocytosis
Mast cell leukemia
Hereditary pyropoikilocytosis